Identification of Drug Targets in Helicobacter pylori by in silico Analysis: Possible Therapeutic Implications for Gastric cancer

• Published in: Current cancer drug targets Vol. 16; no. 1; p. 79
• Main Authors: Nammi, Deepthi, Srimath-Tirumala-Peddinti, Ravi C P K, Neelapu, Nageswara Rao R
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2016
• Subjects: Antineoplastic Agents - therapeutic use; Helicobacter pylori - drug effects; Stomach Neoplasms - drug therapy
• ISSN: 1873-5576
• DOI: 10.2174/1568009615666150602143239

Helicobacter pylori colonize stomach, inducing gastritis, ulcers and gastric cancer. Drugs are used to relieve pain, but not H. pylori infections. Hence, there is a need for discovery of drug targets and drugs for H. pylori. An objective of this current study is to identify drug targets for H. pylori. RAST was used to compare genomes of 23 H. pylori strains with Homo sapiens sapiens, other Helicobacter species (H. acinonychis, H. hepaticus, H. mustalae) and among them, to identify 13471 unique genes. Bacterial genes which are non-homologous to humans and essential for pathogen are identified using BLASTp. Later, 29 potential drug targets were identified by subjecting these genes to property analysis. Eleven of the 29 drug targets are already experimentally validated, lending credence to our approach. These methods have enabled rapid identification of drug targets with possible therapeutic implications for gastric cancer.